Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
Cybin (CYBN) found that its formulation of inhalable DMT has 41% improved bioavailability compared with regular inhaled DMT and lasts 3x longer than IV DMT, extending the therapeutic window.